Articles
-
Minimizing Variability in Imaging Reads for Clinical trials
Minimizing Variability in Imaging Reads for Clinical trials In oncology, response to treatment is typically assessed by measuring tumor size and growth over time using medical images obtained from various imaging modalities. Medical images can provide unreliable results if standardization protocols are not implemented and carefully followed. A thorough understanding of quantitative imaging, its potential […]
-
Putting patient needs first improves engagement – from recruitment to their last medical image.
Putting patient needs first improves patient engagement in a clinical trial, and delivers a better experience for everyone involved – from recruitment to their last medical image. The statistics are staggering. In March of this year The Journal of Oncology Practice published ‘’The State of Cancer Care in America, 2017: A Report by the American […]
-
Making Volumetric Tumor Measurements: The Nuts and Bolts
Going Beyond RECIST – Part 3 Making Volumetric Tumor Measurements: The Nuts and Bolts [Part 3 of our 3 Part series on Going Beyond RECIST: a look at volumetric and functional tumor analysis in oncology clinical trials.] Volume-based measurements and functional imaging, which encompass the whole tumor and reflect physiological changes, can be used to […]
-
Why It’s Important to Add Volume Data to a Clinical Study
Going Beyond RECIST – Part 2 Why It’s Important to Add Volume Data to a Clinical Study [Part 2 of our 3 Part series on Going Beyond RECIST: a look at volumetric and functional tumor analysis in oncology clinical trials.] Capturing tumor volume data during a clinical trial can add significant value to a study. […]
-
Are Volumetric Assessments a True Reflection of Drug Response?
Going Beyond RECIST – Part 1 Are Volumetric Assessments a True Reflection of Drug Response? [Part 1 of our 3 Part series on Going Beyond RECIST: a look at volumetric and functional tumor analysis in oncology clinical trials.] Medical imaging is an integral part of oncology clinical trial design due to its non-invasive nature and […]